Genetic risk test study aims to understand prostate cancer screening choices
NCT ID NCT07197723
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study looks at how people with BRCA1/2 gene mutations react to additional genetic risk testing for prostate cancer. Researchers want to understand how this information affects their decisions about cancer screening. The study involves 150 men aged 45-70 who carry a BRCA1/2 mutation but do not have prostate cancer. It does not test a treatment, but rather gathers insights on decision-making and emotional responses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA1/2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Man's best friend as cancer detector: can dogs sniff out prostate cancer?
- Can a single radiation type spare prostate cancer patients from extra side effects?
- New scan could reveal hidden cancer in High-Risk prostate patients
- Promising prostate cancer combo trial pulled before starting
- New scan could revolutionize prostate cancer monitoring
- New immunotherapy combo targets High-Risk prostate cancer before and after surgery